Key Takeaways
- Eli Lilly acquires Orna Therapeutics for up to $2.4 billion to enhance its in vivo CAR-T cell therapy pipeline.
- Orna’s technology utilizes engineered circular RNA to develop potentially more effective therapies for autoimmune diseases.
- The move aligns with industry trends as major companies invest in in vivo CAR-T research and development.
Acquisition Details
Eli Lilly has made a significant investment in the emerging field of in vivo CAR-T therapies by acquiring Massachusetts-based Orna Therapeutics for up to $2.4 billion. Orna is known for its innovative engineered circular RNA platform, which aims to provide cell therapies developed within a patient’s own body. The centerpiece of this pipeline is ORN-252, a CD19-targeting therapy that Lilly describes as “clinical trial-ready,” primarily aimed at treating B-cell-driven autoimmune diseases.
The specific financial breakdown of the acquisition has not been disclosed, including how much of the $2.4 billion will be paid upfront versus contingent on clinical development milestones.
Innovative Technology
Orna’s approach combines its circular RNA technology with lipid nanoparticles to enhance the durability of therapeutic protein expression. This advancement may enable treatments that are currently not viable with existing RNA or cell therapy mechanisms. As Lilly stated in a recent release, this acquisition represents a strategic expansion into genetic medicine and in vivo cell engineering, positioning the company as a leader in developing novel therapies in this space.
Market Context
Lilly’s acquisition of Orna follows a trend in the pharmaceutical industry where major companies invest heavily in in vivo CAR-T technologies. Notable peers include Gilead Sciences, which purchased Interius BioTherapeutics for $350 million, and AbbVie, which acquired Capstan Therapeutics for $2.1 billion. Bristol Myers Squibb and AstraZeneca have also recently made significant acquisitions in this arena.
Lilly’s interest in in vivo CAR-T solutions has been evident for several months, indicated by their recruitment of a director of CAR-T biology to spearhead development efforts. Francisco Ramírez-Valle, M.D., Ph.D., head of immunology research at Lilly, underscored the potential of CAR-T therapies in addressing autoimmune diseases while noting the challenges associated with current ex vivo treatment methods.
Orna’s Foundational Work
Founded in 2021, Orna Therapeutics has raised $100 million to fuel its mission to deliver CAR therapies directly to patients. Their progress has been underpinned by research from MIT, leading to key collaborations with pharmaceutical giants such as Merck & Co. and Vertex. Recently, Orna also acquired Renegade Therapeutics to expand its capabilities.
Orna’s CEO, Joe Bolen, Ph.D., expressed enthusiasm for the partnership with Lilly, highlighting the potential of their circular RNA technology in developing effective therapies for a variety of B-cell-driven autoimmune conditions.
Lilly’s Future Aspirations
Backed by profits from their successful product Mounjaro, Lilly has been active in increasing its portfolio, recently acquiring Verve Therapeutics for $1 billion and Ventyx for $1.2 billion, among others. The company aspires to be at the forefront of global innovation in therapeutics, showcasing a commitment to expand its impact in the biotech sector.
The content above is a summary. For more details, see the source article.